Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Pliant Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Pliant Therapeutics, Inc.’s stock price such as:

• Pliant Therapeutics, Inc.’s current stock price and volume
• Why Pliant Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for PLRX from analysts
• PLRX’s stock price momentum as measured by its relative strength

About Pliant Therapeutics, Inc. (PLRX)

Before we jump into Pliant Therapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company’s lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Want to learn more about Pliant Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Pliant Therapeutics, Inc..

Pliant Therapeutics, Inc.’s Stock Price as of Market Close

As of February 11, 2025, 4:00 PM, CST, Pliant Therapeutics, Inc.’s stock price was $2.605.

Pliant Therapeutics, Inc. is down 15.15% from its previous closing price of $3.070.

During the last market session, Pliant Therapeutics, Inc.’s stock traded between $2.600 and $3.070. Currently, there are approximately 60.73 million shares outstanding for Pliant Therapeutics, Inc..

Pliant Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Pliant Therapeutics, Inc. Stock Price History

Pliant Therapeutics, Inc.’s (PLRX) price is currently down 75.77% so far this month.

During the month of February, Pliant Therapeutics, Inc.’s stock price has reached a high of $12.880 and a low of $2.600.

Over the last year, Pliant Therapeutics, Inc. has hit prices as high as $18.000 and as low as $2.820. Year to date, Pliant Therapeutics, Inc.’s stock is down 80.22%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Pliant Therapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. However, as of February 10, 2025,, no analysts have changed their rating of Pliant Therapeutics, Inc.’s stock over the last month.

Additionally, you'll want to evaluate Pliant Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Pliant Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Pliant Therapeutics, Inc. (PLRX) by visiting AAII Stock Evaluator.

Relative Price Strength of Pliant Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of February 10, 2025, Pliant Therapeutics, Inc. has a weighted four-quarter relative price strength of -36.30%, which translates to a Momentum Score of 3 and is considered to be Very Weak.

Want to learn more about how Pliant Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Pliant Therapeutics, Inc. Stock Price: Bottom Line

As of February 11, 2025, Pliant Therapeutics, Inc.’s stock price is $2.605, which is down 15.15% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Pliant Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.